Lefamulin manufacturers
- Lefamulin
-
- $35.00
-
2026-06-02
- CAS:1061337-51-6
- Purity: 99.63%
- Supply Ability: 10g
- Lefamulin
-
-
2025-03-21
- CAS:1061337-51-6
- Purity: 99%
- Supply Ability: 1000KGS
|
| | Lefamulin Basic information |
| Product Name: | Lefamulin | | Synonyms: | Lefamulin;2-[[(1R,2R,4R)-4-Amino-2-hydroxycyclohexyl]thio]acetic acid (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester;BC 3781;Lefamulin(BC-3781);Acetic acid, 2-[[(1R,2R,4R)-4-amino-2-hydroxycyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester;(3aR,4R,5R,7S,8S,9R,9aS,12R)-8-Hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-(((1R,2R,4R)-4-amino-2-hydroxycyclohexyl)thio)acetate;Lefamulin, 10 mM in DMSO | | CAS: | 1061337-51-6 | | MF: | C28H45NO5S | | MW: | 507.73 | | EINECS: | | | Product Categories: | API | | Mol File: | 1061337-51-6.mol |  |
| | Lefamulin Chemical Properties |
| Boiling point | 618.6±55.0 °C(Predicted) | | density | 1.19±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMF: 16 mg/mL; DMSO: 12 mg/mL; Ethanol: 3 mg/mL; PBS (pH 7.2): 0.25 mg/mL | | form | A solid | | pka | 14.45±0.60(Predicted) | | color | White to off-white | | InChIKey | KPVIXBKIJXZQJX-FCEONZPQSA-N | | SMILES | C(O[C@@H]1C[C@](C=C)(C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@]2([H])C(=O)CC3)(=O)CS[C@@H]1CC[C@@H](N)C[C@H]1O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | STOT SE 2 |
| | Lefamulin Usage And Synthesis |
| Uses | Lefamulin is an antibiotic medication used in the treatment of adults with community-acquired bacterial pneumonia. | | Biological Activity | Lefamulin inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome. Specifically, it binds to the peptidyl transferase center of the ribosome and inhibits the transfer of amino acids to growing polypeptide chains, which leads to the inhibition of bacterial protein synthesis and bacterial death. Lefamulin is active against a wide range of Gram-positive bacteria, including Streptococcus pneumoniae, Staphylococcus aureus, and methicillin-resistant S. aureus (MRSA), as well as some atypical bacteria such as Legionella species. It has also been shown to have activity against some Gram-negative bacteria, including Haemophilus influenzae and Moraxella catarrhalis. | | Synthesis | synthesis route of Lefamulin
 | | in vivo | Lefamulin (10-140 mg/kg, s.c.) shows anti-inflammatory effect on LPS-induced lung neutrophilia mouse model[4].
Lefamulin (1.25-160 mg/kg, s.c.) shows antibacterial effect in S. pneumoniae or S. aureus challenged lung infection mice[5].
| Animal Model: | LPS-induced lung neutrophilia mouse model[4] | | Dosage: | 10-140 mg/kg | | Administration: | Subcutaneous injection (s.c.) | | Result: | Reduced BALF neutrophil cell counts.
Reduced pro-inflammatory cytokine (TNF-α, IL-6, IL-1β, and GM-CSF), chemokine (CXCL-1, CXCL-2, and CCL-2) and MMP-9 levels in mouse lung tissue.
|
|
| | Lefamulin Preparation Products And Raw materials |
| Raw materials | Cyclohexene, 4-isocyanato-, (4R)--->Acetic acid, 2-[[(1R,2R,4R)-2-hydroxy-4-[(2,2,2-trifluoroacetyl)amino]cyclohexyl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester-->1350636-88-2-->tert-butyl N-[(1R)-cyclohex-3-en-1-yl]carbamate-->tert-butyl N-[(1R,3R,4R)-3-hydroxy-4-sulfanylcyclohexyl]carbamate-->TiaMulin Related CoMpound A-->{(1R,2R,4R)-4-[(tert-butoxycarbonyl)-amino]-2-hydroxy-cyclohexyl} benzene-carbothioate-->(R)-(+)-3-Cyclohexenecarboxylic acid-->3-Cyclohexenecarboxylic acid | | Preparation Products | Lefamulin acetate |
|